Related Experiment Video

Updated: Nov 16, 2025

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.2K

IL12Rβ1 Partial Agonists Are Active with Reduced Toxicity In Vivo

    Cancer Discovery
    |February 27, 2021
    PubMed

    IL12-like partial agonists of IL12Rβ1 activated cytotoxic T cells but not natural killer (NK) cells.

    More Related Videos

    Development of Recombinant Proteins to Treat Chronic Pain10:37

    Development of Recombinant Proteins to Treat Chronic Pain

    Published on: April 11, 2018

    9.8K
    Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling09:51

    Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

    Published on: July 26, 2017

    12.7K

    Related Concept Videos

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
    290